A PHASE I, OPEN LABEL, NON-RANDOMIZED, SINGLE-DOSE, PARALLEL-COHORT, MATCHED-CONTROL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF AVANAFIL (TA-1790) IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY CONTROL MALE SUBJECTS.

Trial Profile

A PHASE I, OPEN LABEL, NON-RANDOMIZED, SINGLE-DOSE, PARALLEL-COHORT, MATCHED-CONTROL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF AVANAFIL (TA-1790) IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY CONTROL MALE SUBJECTS.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2011

At a glance

  • Drugs Avanafil (Primary)
  • Indications Erectile dysfunction
  • Focus Pharmacokinetics
  • Sponsors VIVUS
  • Most Recent Events

    • 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jan 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top